drugset / Trial / NCT01035879
Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of MBX-2982 Administered Daily for 4 Weeks as Monotherapy in Patients With Type 2 Diabetes
RandomizedParallel-groupTriple-blindTreatment
Summary
To define the relative efficacy, safety and tolerability profiles of oral daily MBX-2982 at three different daily doses vs. placebo and sitagliptin 100 mg when administered for up to 4 weeks in patients that are treatment-naive or taking a single anti-diabetic medication (non-TZD, non-injectable).
Timeline
- Start
- 2009-12
- Primary completion
- 2010-08
- Completion
- 2010-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MBX-2982 | Small molecule | 25 mg | — |
| Subject | MBX-2982 | Small molecule | 100 mg | — |
| Subject | MBX-2982 | Small molecule | 300 mg | — |
| Comparator | Sitagliptin | Small molecule | 100 mg | — |